PRACTICE MANAGEMENT

AvKARE bottles mix Viagra generics with antidepressant, triggering recall

AvKARE | December 15, 2020

A conventional drugmaker with a Rolodex loaded with government customers is pulling an energizer and an erectile brokenness medications after the two were bundled together in similar containers.

Pulaski, Tennessee-based AvKARE reviewed one parcel of sildenafil 100-mg tablets and one parcel of trazodone 100-mg tablets after the items were stirred up by an outsider bundling provider, the organization said before the end of last week. The jugs had just been delivered to drug stores.

AvKARE markets its own private-name conventional medications to a record of government customers, including the branches of Defense, Veterans Affairs and the Health and Human Services. The organization additionally supplies the Indian Health Services, in addition to nongovernment clients around the world.

The customer level review influences parts sent to merchants and wholesalers and afterward delivered out from one side of the country to the other, the organization said. The sildenafil part has a March 2022 termination date, while the trazodone parcel lapses in June 2022.

AvKARE said it so far hasn't got any result reports from the reviewed parcels. Sildenafil—a nonexclusive rendition of Viagra—can blend inadequately with nitrate-containing drugs for diabetes, hypertension or coronary illness, conceivably bringing pulse down to perilous levels.

The upper trazodone hydrochloride, in the interim, can cause sluggishness, dazedness, stoppage and obscured vision, AvKARE cautioned. Those results represent a more serious danger of falls and impeded driving in more seasoned clients who may have bought the organization's erectile brokenness copycat.

Spotlight

Modern-day research produces a vast amount of information. The cloud provides a solution for those drowning in this data deluge, and this infographic reviews how cloud-based solutions work and how they can benefit your research.

Spotlight

Modern-day research produces a vast amount of information. The cloud provides a solution for those drowning in this data deluge, and this infographic reviews how cloud-based solutions work and how they can benefit your research.

Related News

RESEARCH

Nanoform Releases Next-Generation AI-based Drug selection Tool

Nanoform | March 23, 2021

Nanoform innovative nanoparticle medicine enabling company next generation of its STARMAP® AI artificial intelligence platform nanoparticle bioavailability excipient microns nm CESS technology silico pharma drugs lifecycle managementNanoform, an innovative nanoparticle medicine enabling company, has today dispatched the next generation of its STARMAP® AI (artificial intelligence) platform, v2.0. The technology uses scanty information AI to expand trial results from its CESS® nanoparticle designing process with detailed master information, permitting dependable expectations to be made in regards to accomplices' likely success of nanoforming their medication atoms. CESS® is a nanoparticle platform technology which produces unadulterated homogeneous medication particles from arrangement in a without excipient process. By diminishing the molecule size e.g., from 10 microns to 50 nm, the particular surface territory can be expanded by as much as 1000-crease, subsequently improving disintegration rate, solvency, and bioavailability. Subsequently, Nanoform can help pharma accomplices progress atoms into advancement that in any case might not have been conceivable. It additionally opens up energizing opportunities for a wide scope of novel medication conveyance applications. STARMAP® is a computerized form of the CESS® technology that empowers in silico tries in enormous amounts, making quick forecasts of which atoms ought to be nanoformed. This is significant since there are more potential medication atoms than particles in the known universe. STARMAP® can be a useful asset for pharma accomplices to pick appropriate medication contender for additional improvement from their huge libraries. The benefits may incorporate quicker way to advertise and additional opportunities for widening and extending drug pipelines while at the same time expanding the likelihood of medication improvement success. The STARMAP® platform can have wide materialness in drug disclosure and advancement just as in lifecycle management for existing promoted drugs and 505b2-like item improvement methodologies. "AI algorithms developed for big data have so far struggled to live up to expectations in pharma because the data, especially for early assets (drug discovery, drug screening), that is available to pharma is typically insufficient for generating reliable predictions. We believe sparse-data AI will work much better - in practice, this means augmenting experimental results with detailed expert knowledge, which can be used to prevent the AI from predicting outcomes that are nonsensical based on prior understanding. There is a lot of untapped potential in sparse-data AI for the pharma industry and the field continues to undergo rapid development in both academia and the industry in general," said Prof. Jukka Corander, Head of AI at Nanoform. "By determining which drug candidates are ideal for our CESS® process, the next-gen STARMAP® platform can potentially create new opportunities for our pharma partners. These can include both revisiting drug candidates unnecessarily discarded by AIs trained on old particle engineering techniques, and rapidly picking winners among new drug candidates. Ultimately, the benefit of more advanced AI will be felt by patients as new therapies are accelerated to market," commented Christian Jones, Chief Commercial Officer at Nanoform

Read More

BUSINESS INSIGHTS

MATRIC to Establish First and Only National Center of Excellence for Pharmaceutical Process Design

The Mid-Atlantic Technology, | March 03, 2022

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a result of the Department of Commerce’s recent Rapid Assistance (for) Coronavirus Economic Response grant to the RAPID Manufacturing Institute, of which MATRIC is a sub-awardee. MATRIC—applying its unique infrastructure and subject matter expertise—will lead the specialty chemical manufacturing industry with this Center of Excellence focused on accelerated process design through modular processing. Onshoring the capability to move critical pharmaceutical material manufacturing processes from concept to commercial products will enable faster response times and fewer supply chain disruptions for the Nation. “Today, the U.S. doesn’t have the manufacturing capability to produce some key raw materials and intermediates at scale to support our pharmaceutical industry and needs. The COVID pandemic and the current global supply chain issues have taught us the importance of supply chain stability and security, and this starts with critical raw materials produced domestically, distributed with purpose, and efficiently accessed.” MATRIC Chairman & CEO Steven B. Hedrick “At the beginning of the COVID pandemic, we struggled to get our families and front-line healthcare workers access to necessary PPE, disinfectants and other critical equipment. I applaud MATRIC for making this exciting investment and establishing the Center for Excellence right here in West Virginia. Their broad-based chemical technology expertise will also help improve domestic Active Pharmaceutical Ingredient (API) manufacturing, at a time when onshoring our pharmaceutical supply chain is critical,” said U.S. Senator Joe Manchin (D-WV). “West Virginia’s strategic location and MATRIC’s unique skillset will play a critical role in ensuring healthcare professionals across the country can quickly and efficiently get the equipment they need to safely do their jobs.” Collaboration MATRIC is a sub-awardee of the RACER grant from the Department of Commerce to the RAPID® Manufacturing Institute (RAPID). MATRIC will collaborate with RAPID, the project leader, and with partners at Teich Process Development and Procegence. “Through its partnership with RAPID, Teich and Procegence, MATRIC’s Center of Excellence avails our economy with choices. Choices like this afford the opportunity to source from Americans for Americans, or to selectively buy from overseas, at their discretion,” said RAPID Executive Director & Chief Technology Officer Ignasi Palou-Rivera. “Just on the horizon, the most important raw materials and intermediates for pharma will again be made available inside the United States and not be locked down by a relatively inelastic supply chain originating in nations with substantial government control.” RACER grants are awarded by the U.S. Department of Commerce to high-impact projects designed to fund awards for research, development, and testbeds to prevent, prepare for, and respond to coronavirus. About MATRIC MATRIC is the strategic innovation partner of choice that provides uncommon expertise and infrastructure to solve the most challenging science and technology problems. Focusing on the areas of chemical, energy and environmental technologies, technical engineering and advanced software technologies, MATRIC delivers innovation from concept to commercialization. We utilize our experienced and renowned staff, unique laboratory and pilot plant facilities, and flexible intellectual property models to create value for customers and investors around the world. We are an energized and expanding company that works from facilities in South Charleston and Morgantown, W.Va. About RAPID® Manufacturing Institute RAPID serves as a nexus between process innovation, economic development, and job creation. The technology development and educational programming we sponsor will increase energy and operational efficiencies, enhance productivity, and improve sustainability, making U.S. manufacturing in the chemical process industries (CPI) more competitive in the global market and developing the next generation workforce for these industries.

Read More

PHARMA TECH

Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Phio Pharmaceuticals Corp | October 26, 2020

Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020.

Read More